ログイン 会員登録
icon_bulk_order一括注文 Acrobiosystems for English
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
phone
Your Position: ホーム > MIF

MIF

概要

Name:Macrophage migration inhibitory factor
Target Synonym:EC:5.3.2.1,GIF,EC 5.3.3.12,EC 5.3.2.1,Macrophage Migration-Inhibitory Factors,Epididymis Secretory Sperm Binding Protein,EC:5.3.3.12,Phenylpyruvate Tautomerase,L-Dopachrome Tautomerase,MMIF,Glycosylation-inhibiting factor,L-dopachrome isomerase,MIF,Macrophage Migration Inhibitory Factor,Macrophage Migration Inhibitory Factor (Glycosylation-Inhibiting Factor),GLIF
Number of Launched Drugs:1
Number of Drugs in Clinical Trials:1
Lastest Research Phase:Approved

製品リスト製品比較と製品注文

製品仕様別:
製品カテゴリー別:
種類別:
タグ別:
コンジュゲート:
製造番号 種類 製品説明 構造 純度 特徴
MIF-H82E7 Human Biotinylated Human MIF Protein, His,Avitag™
MIF-H82E7-structure
MIF-H82E7-sds
ACRO Quality

カスタマーレビュー

Synonym Name

MIF,GLIF,MMIF,GIF

Background

Macrophage migration inhibitory factor(MIF) is also known as Glycosylation-inhibiting factor(GIF), L-dopachrome isomerase, L-dopachrome tautomerase, Phenylpyruvate tautomerase. Interacts with CXCR2 extracellular domain, CD74 extracellular domain, COPS5 and BNIPL.  The expression of MIF at sites of inflammation suggests a role as mediator in regulating the function of macrophages in host defense. Counteracts the anti-inflammatory activity of glucocorticoids. Has phenylpyruvate tautomerase and dopachrome tautomerase activity (in vitro), but the physiological substrate is not known. It is not clear whether the tautomerase activity has any physiological relevance, and whether it is important for cytokine activity.

Clinical and Translational Updates

公開薬物情報

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Ibudilast AV-411; KC-404; MN-166 Approved Ketas, Pinatos, Eyevinal Japan Asthma; Multiple Sclerosis; Neuralgia Kyorin Pharmaceutical Co Ltd 1989-01-01 Alcohol-Induced Disorders; Substance-Related Disorders; HIV Infections; Diabetic Neuropathies; Headache Disorders, Secondary; Opioid-Related Disorders; Multiple Sclerosis, Chronic Progressive; Multiple Sclerosis; Pneumonia, Viral; Alcoholism; Asthma; Neuralgia; Amyotrophic Lateral Sclerosis Details

臨床試験情報

Name Research Code Research Phase Company Indications Clinical Trials
IPG-1094 IPG-1094; IPG-001 Phase 1 Clinical Nanjing Immunophage Biotech Co Ltd Hematologic Neoplasms; Solid tumours; Multiple Sclerosis; Multiple Myeloma; Psoriasis Details

This web search service is supported by Google Inc.

totopphone